can also treat the second most common type – dementia with Lewy bodies (DLB). The treatment is a cholinesterase inhibitor (ChEI): it's already been used with DLB patients, but up until now it was ...

There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to ...

Researchers from DZNE and Otto von Guericke University Magdeburg have identified individuals with increased risk for dementia ...

Variations in the use of antidementia and antipsychotic drugs for nursing home residents with dementia across the United ...

A new study, however by the universities of Manchester, Nottingham, Edinburgh and Dundee, published in the BMJ, has found that antipsychotic drugs prescribed to dementia patients cause more ... light ...

Researchers from DZNE and University Magdeburg have identified individuals with increased risk for dementia using mobility data, recorded during a smartphone-based wayfinding task on the university ...

Managing dementia in the complex landscape of neurological disorders stands out as a formidable challenge, affecting millions ...

An examination of the cardiovascular risks, side effects associated with use of lecanemab therapy in patients with cardiovascular disease.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

Using advanced artificial intelligence algorithms, scientists are hoping to identify brain wave patterns associated with the risk of dementia.

Its use there has soared, as it has almost everywhere. Weight-loss drugs like Ozempic and Wegovy seemed to work magic when they were launched and are quickly being joined by other drugs that work ...